The group experienced a 11.6% reduction in total weight loss after 24 weeks compared to 4.9% in the control group.
Liraglutide treatment led to a significant estimated treatment difference in weight loss of 6.6%.
The adjusted mean weight reduction for the liraglutide group was -6.2 kg, while the control group had a lesser reduction.
Participants treated with liraglutide also showed a greater decrease in BMI of -3.0 kg/m compared to controls.
Increased rates of remission for non-alcoholic fatty liver disease and hypertension were observed in the liraglutide group.
No serious adverse reactions were reported during the study.
Simplified
INTRODUCTION: The safety and efficacy of as a weight loss intervention in individuals who remain obese within 1 year post-metabolic surgery remain unclear. This study aimed to evaluate the effects and safety of liraglutide (1.8 mg) in patients with persistent obesity at 6 months postoperatively.
METHODS: This retrospective cohort study included 61 patients who remained obese (body mass index [BMI] ≥ 28.0 kg/m) at 6 months postoperatively. Among these patients, 27 were treated with 1.8 mg of liraglutide for 12 weeks, whereas 34 served as controls. The primary endpoint was the change in total weight loss (%TWL) after 24 weeks. Changes in weight, BMI, complications, and adverse events were also assessed. 2
RESULTS: The liraglutide group showed a greater reduction in %TWL than the control group (11.6% ± 1.1% vs. 4.9% ± 1.0%), with an estimated treatment difference of 6.6% (95% confidence interval [CI], 3.7-9.6%, P < 0.01). The adjusted mean differences in the reduction of weight and BMI between the liraglutide and control groups were - 6.2 kg (95% CI - 8.9 to - 3.4, P < 0.01) and - 3.0 kg/m(95% CI - 4.2 to - 1.7, P < 0.01), respectively. The liraglutide group exhibited increased rates of remission in non-alcoholic fatty liver disease and hypertension. No serious adverse reactions were observed. 2
CONCLUSIONS: For patients who remained obese at 6 months postoperatively, 12-week liraglutide treatment resulted in increased weight loss, improved metabolic control, and high rate of remission for obesity-related metabolic diseases after 24 weeks. Earlier and more timely adjuvant weight loss medication intervention based on BMI within 1 year postoperatively may enhance weight loss after metabolic surgery. Graphical abstract available for this article.
Key numbers
6.6%
Increase in %TWL
Estimated treatment difference between and control groups.
6.2 kg
Weight reduction
Adjusted mean difference in weight loss between groups.
3.0 kg/m
reduction
Adjusted mean difference in between and control groups.
Full Text
We can’t show the full text here under this license.
Declarations Conflict of Interest Yuanyuan Shen, Yuanhao Huang, and Yuqin Ouyang; Xinyue Xiang, Xuehui Chu, Bingqing Zhang, Tao Han, Wenjuan Tang, and Wenhuan Feng have no conflicts of interest to disclose. Ethical Approval The trial was conducted in accordance with the principles embodied in the Declaration of Helsinki and was approved by the Ethics Committee of the Affiliated Drum Tower Hospital, Medical School, Nanjing University (approval no.: 2017–030-08). All patient anonymity was preserved. All participants provided informed consent for their data potentially being used in the study.
